Tomorrow’s Medicine
Thomas Morrow, MD

Thomas Morrow, MD

Taltz is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is delivered as a subcutaneous injection. The agent comes as either a pre-filled syringe or an autoinjector and can be self-injected after proper training and with physician supervision.
By some measures, the financial and health toll from inflammatory bowel disease, rheumatoid arthritis, and psoriasis is comparable to stroke and lower back pain. Collectively, they affect about 10 million patients in the United States. They are chronic conditions characterized by immune-mediated inflammation of unknown etiology and for which there is no cure.
News & Commentary
“This is not altogether surprising as only 69% of children’s hospitals successfully attested to Stage 1 of the CMS Medicaid EHR Incentive Program and psychiatric hospitals are not eligible for the CMS Medicaid or Medicare EHR Incentive Program,” according to a data brief by the Office of the National Coordinator for Health Information Technology.
Paul Terry
President and CEO, HERO

 A few days ago, I went to the “Poke-stop” in my small town of Waconia, Minnesota, (population 11,490) to learn why I was losing my Pokémon “gym battles” and, more importantly, to survey the growing numbers of twentysomethings exploring my community’s parks and landmarks. I met a group of 15 Waconians for the first time, and they were excited about describing how Pokémon Go had increased their activity levels, their awareness of our community’s history, and their engagement with others.

Value-Based Care
Michael D. Dalzell
Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Saskia Siderow
Allison Silvers, MBA
Diane E. Meier, MD
Palliative care has become America’s fastest growing medical specialty. ere are now more than 6,500 physicians and 13,500 nurses certified in palliative care, and palliative care teams available in more than 80% of American hospitals with more than 50 beds.
Thomas Reinke
The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

The aggressive shift from volume to value has all stakeholders—payers, providers, and pharma—considering what they can do to stay relevant. McKesson recently commissioned a national survey to assess the volume-to-value progress of hospitals and payers. It’s looking pretty good, according to the results of the survey that included 350 hospitals and 115 payers. The payers reported that they were 58% along the continuum toward full value-based reimbursement, a 10% increase since 2014. Hospitals weren’t far behind, reporting that they were 50% along the value continuum, up 4% in the past 2 years. 

News & Commentary
The annual hospitalization rate for people with RA dived 67%, from 13.9 per 100,000 American adults in 1993 to 4.6 in 2011. Meanwhile, the hospitalization rate for those with gout doubled, from 4.4 to 8.8 per 100,000 Americans adults.
Thomas Reinke

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.